## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 1.88 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($190.72)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Cardinal Health (CAH): Assessing Valuation After a Recent Pullback in the Share Price**
- Source: Simply Wall Street | 20251215T144158 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) has experienced a recent 4% pullback despite a strong year, leading to investor consideration of its long-term uptrend. The company is perceived as undervalued, with a narrative fair value of $216.60 and an SWS DCF model suggesting an intrinsic value of $461.54, driven by expected operational efficiencies and cash flow improvements from investments in technology and distribution. However, regulatory scrutiny on drug pricing and potential slowdowns in pharma volumes pose risks to optimistic earnings assumptions.

**2. Nomura Holdings Inc. Acquires 72,525 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251215T110907 | Bullish | Relevance: 100%
- Nomura Holdings Inc. significantly increased its stake in Cardinal Health, Inc. by 568%, purchasing 72,525 additional shares in Q2, bringing its total holdings to $14.33 million. This comes as Cardinal Health beat Q3 earnings expectations and set strong FY2026 guidance, leading analysts to maintain a "Moderate Buy" rating with an average target price of $209.00. The company also declared a quarterly dividend of $0.5107 per share.

**3. Holocene Advisors LP Sells 187,664 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251214T125201 | Somewhat-Bullish | Relevance: 100%
- Holocene Advisors LP reduced its stake in Cardinal Health, Inc. by 19% in the second quarter, selling 187,664 shares and now holding 797,812 shares valued at approximately $134.03 million. Cardinal Health recently reported strong earnings, exceeding analyst expectations, and provided positive FY2026 guidance. Analysts maintain a "Moderate Buy" rating with a consensus target of $209.00, and the company announced a quarterly dividend.

**4. Barclays Initiates Coverage on Cardinal Health (CAH) with Overweight Rating**
- Source: Finviz | 20251211T130802 | Bullish | Relevance: 100%
- Barclays has initiated coverage on Cardinal Health (CAH) with an Overweight rating and a $243 price target, citing its strong performance and shift towards higher-margin healthcare areas like specialty pharmaceuticals. The company's recent acquisition of Solaris Health further expands its multi-specialty MSO platform, contributing to a 22% increase in total Q1 2026 revenue. The firm is most optimistic about drug distributors within the healthcare technology and distribution sector.

**5. Is Cardinal Health Stock Outperforming the Nasdaq?**
- Source: inkl | 20251210T130730 | Bullish | Relevance: 100%
- Cardinal Health (CAH) has significantly outperformed the Nasdaq Composite ($NASX) over the past three months, six months, and 52 weeks, driven by strong sentiment and solid earnings. The healthcare services and products firm reported a 22% year-over-year revenue increase and a 36% non-GAAP EPS increase in Q1 fiscal 2026, leading to a raised outlook. Analysts maintain a "Strong Buy" rating with an expected upside.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +4.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.88 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.1B |
| Beta | 0.64 |
| 52W Range | $114.60 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.88 |
| Forward P/E | 17.9 |
| Current P/E | 20.2 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.4% to 0.2% (+4.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-2.62), momentum weakening. RSI neutral at 50. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.17% (CS: 30) | Neutral |
| RSI_14 | 50.3 | Neutral |
| MACD Histogram | -2.62 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.256x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $198.18
- **Stop Loss:** $190.72 (3.8% risk)
- **Target:** $205.64 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 134
- **Position Value:** $26,556.12
- **Portfolio %:** 26.56%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*